Suzhou Shanwan Biopharmaceutical Technology

Suzhou Shanwan Biopharmaceutical Technology is a biopharmaceutical company established in December 2018, specializing in long-acting and controlled-release drug delivery technologies. The company's core focus is on the research, development, and application of in-situ gelling formulations, a type of complex injectable preparation. This technology is designed to upgrade conventional drug formulations to provide sustained-release, targeted delivery, and improved bioavailability.

The company was founded by Yao Zhichao, who serves as the chairman, and co-founded by Qi Yanfeng, the general manager. Qi Yanfeng has prior experience teaching at Tulane University in the USA and was recognized as a science and technology leader in the Wujiang district in 2020. He leads the development of the core technology, which is based on the Atrigel patent. The company operates from Suzhou's Wujiang District, a strategic location within the Yangtze River Delta.

Shanwan Bio provides a range of services, including Contract Development and Manufacturing Organization (CDMO) services, formulation development, and pharmaceutical research. It operates GMP-compliant production workshops capable of handling various formulations such as in-situ gel suspensions, pre-filled syringes, and lyophilized powders. The business model integrates in-house product development with third-party formulation services (CDMO), serving clients in the pharmaceutical industry. The company's own pipeline includes small molecule drugs and peptides, with a particular expertise in peptide-based in-situ gel formulations. One of its primary in-house products is an injectable Leuprolide Acetate, used for treating hormone-related diseases like breast and prostate cancer.

Since its inception, Shanwan Bio has progressed through several funding rounds. After an angel round in 2019, it secured Pre-A funding in 2021, A and A+ rounds in 2021 and 2022 respectively, and a Series B round in April 2025. The Series B funding, amounting to tens of millions of RMB, was led by Lianyungang Jinqiao Emerging Industry Fund and is intended to advance clinical trials and establish an in-situ gel drug production base.

Keywords: in-situ gel, long-acting release, drug delivery, controlled-release injectables, biopharmaceutical, CDMO, peptide drugs, formulation development, Leuprolide Acetate, complex formulations, pharmaceutical manufacturing, drug delivery systems, sustained release, bioavailability enhancement, GMP production, formulation services, injectable drugs, Atrigel technology, pharmaceutical research, CMO services